Browse: Departments Dates Agencies
SUBJECT CATEGORY: Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting
DOCUMENT SUMMARY:
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.
Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
Times and Dates: 8:30 a.m.5 p.m., February 7, 2001; 8:30 a.m.3:30 p.m., February 8, 2001.
Place: Doubletree Hotel Atlanta Buckhead, 3342 Peachtree Road, NE, Atlanta, Georgia 30326. Phone: 404/2311234.
Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.
Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of
[[Page 80896]]
Health and Human Services, the Assistant Secretary for Health and
Surgeon General, and the Director, CDC, regarding the need for, and the
nature of, revisions to the standards under which clinical laboratories
are regulated; the impact on medical and laboratory practice of
proposed revisions to the standards; and the modification of the standards to accommodate technological advances.
Matters to be Discussed: The agenda will include a discussion on waived testing and status of the process for making waiver determinations, a workgroup report on genetic testing, and updates from CDC, Food and Drug Administration and Health Care Financing Administration.
Agenda items are subject to change as priorities dictate.
Contact Person for Additional Information: Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, M/ S F11, Atlanta, Georgia 303413724, telephone 770/4888042, fax 770/ 4888279.
The Director, Management Analysis and Services office has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Dated: December 18, 2000.
Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 0032750 Filed 122100; 8:45 am]
BILLING CODE 416318P
SUMMARY: Clinical Laboratory Improvement Advisory Committee,
DOCUMENT BODY 2:
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.
Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
Times and Dates: 8:30 a.m.5 p.m., February 7, 2001; 8:30 a.m.3:30 p.m., February 8, 2001.
Place: Doubletree Hotel Atlanta Buckhead, 3342 Peachtree Road, NE, Atlanta, Georgia 30326. Phone: 404/2311234.
Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.
Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of
[[Page 80896]]
Health and Human Services, the Assistant Secretary for Health and
Surgeon General, and the Director, CDC, regarding the need for, and the
nature of, revisions to the standards under which clinical laboratories
are regulated; the impact on medical and laboratory practice of
proposed revisions to the standards; and the modification of the standards to accommodate technological advances.
Matters to be Discussed: The agenda will include a discussion on waived testing and status of the process for making waiver determinations, a workgroup report on genetic testing, and updates from CDC, Food and Drug Administration and Health Care Financing Administration.
Agenda items are subject to change as priorities dictate.
Contact Person for Additional Information: Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, M/ S F11, Atlanta, Georgia 303413724, telephone 770/4888042, fax 770/ 4888279.
The Director, Management Analysis and Services office has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Dated: December 18, 2000.
Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 0032750 Filed 122100; 8:45 am]
BILLING CODE 416318P
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 50 CFR Part 679 47 CFR Part 73 26 CFR Part 1 40 CFR Part 180 33 CFR Part 117 50 CFR Part 17 44 CFR Part 67 50 CFR Part 648 14 CFR Part 97 40 CFR Part 63 33 CFR Part 100 50 CFR Part 622 50 CFR Part 660 26 CFR Part 301 44 CFR Part 65 39 CFR Part 111 40 CFR Part 300 6 CFR Part 5 40 CFR Part 271 47 CFR Part 64 40 CFR Parts 52 and 81 50 CFR Part 665 10 CFR Part 50 44 CFR Part 64 49 CFR Part 571 39 CFR Part 3020